Philippe Camus, M.D.

Dijon, France

Both apps are now back!

Back

The Drug-Induced Respiratory Disease Website and App

I.ae

I - Interstitial/parenchymal lung disease

Radiation recall pneumonitis

Last update 20/10/2016

(Fr: PnP de rappel en territoire préalablement irradié). Radiation recall pneumonitis is when pulmonary opacities develop exactly in the previously-irradiated area of the chest and lung, following the administration of adriamycin, carmustine, doxorubicin, etoposide, gefitinib, gemcitabine, paclitaxel or trastuzumab. Radiation recall on the skin and esophagus can also occur (PMID 24965480)

Causative drugs

19

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Cabazitaxel
I.a
I.ae
Camrelizumab
I.a
I.ae
X.f
XII.d
Carmustine (BCNU)
I.a
I.b
I.g
I.m
I.y
I.ae
II.a
II.e
VI.a
VI.f
VI.m
VI.ac
XII.c
XVI.a
XVI.b
XVI.m
XIX.a
XIX.o
XIX.q
XIX.v
XIX.br
Chemotherapy, antineoplastic
I.a
I.b
I.c
I.e
I.f
I.g
I.i
I.l
I.m
I.n
I.o
I.w
I.x
I.y
I.z
I.ab
I.ae
I.av
II.a
II.b
II.e
II.f
III.a
IV.a
IV.j
V.a
V.g
VI.a
VI.f
VI.ac
VII.b
VII.c
VII.f
VIII.a
VIII.h
IX.f
IX.j
IX.o
X.c
X.d
X.f
X.i
X.m
X.p
XI.b
XI.l
XI.t
XII.a
XII.b
XII.c
XII.f
XII.g
XII.h
XII.m
XII.n
XII.t
XII.ak
XVI.ac
XVI.ad
XVI.bh
XVI.bp
XVI.by
XVIII.g
XIX.d
XIX.e
XIX.o
XIX.q
XIX.x
XIX.ba
XIX.bd
XIX.bx
XX.b
XX.c
XX.e
XX.g
XX.j
XX.r
XX.ae
XXI.a
XXI.b
XXI.d
COVID19 (SARS-CoV2) vaccination/vaccine
I.a
I.b
I.c
I.z
I.ae
I.az
I.bd
II.b
II.e
III.a
III.m
IV.a
IV.c
VII.a
VII.b
VII.ab
IX.r
IX.y
IX.ab
X.b
X.d
X.f
X.h
X.j
X.l
X.o
X.u
X.al
X.bg
X.bh
X.bi
X.bk
XI.b
XII.a
XII.c
XII.d
XII.e
XII.f
XII.h
XII.i
XII.l
XII.n
XII.r
XII.u
XII.ak
XII.bi
XVI.b
XVI.c
XVI.ba
XVIII.a
XVIII.c
XIX.a
XIX.d
Dactinomycin
I.ae
Doxorubicin - Adriamycin
I.e
I.g
I.ae
II.b
II.e
XII.a
XII.g
XII.n
XII.t
XII.ak
XII.be
XIX.d
XXVI.k
Erlotinib
I.a
I.b
I.e
I.g
I.m
I.x
I.ae
II.e
III.a
VI.a
VI.f
XI.t
XII.g
XVI.n
XVI.ad
XVI.ba
XVI.by
XIX.d
XIX.o
XXIII.e
Everolimus
I.a
I.b
I.e
I.f
I.i
I.m
I.n
I.q
I.w
I.z
I.ae
II.e
III.a
III.h
IV.ab
V.a
VI.h
VI.i
VII.a
XVI.b
XVI.bp
XIX.a
XIX.d
XIX.e
XIX.f
XIX.r
XX.e
Gemcitabine
I.a
I.b
I.c
I.d
I.g
I.i
I.m
I.ae
II.a
II.e
II.f
III.a
III.h
IV.f
VI.a
VI.i
VI.m
VII.b
VII.c
VII.f
X.c
X.o
X.p
X.ah
XI.b
XII.c
XII.g
XII.n
XII.u
XVI.a
XVI.b
XVI.n
XIX.a
XIX.f
XIX.o
XIX.r
XX.e
Ifosfamide
I.a
I.g
I.ae
II.a
II.b
XI.a
XII.g
XII.n
XII.o
XIV.a
XIX.v
XIX.w
Immune checkpoint inhibitors (ICI) - ICI combinatorial Rx
I.a
I.b
I.c
I.d
I.e
I.f
I.g
I.v
I.w
I.x
I.z
I.ab
I.ae
I.ak
I.ay
II.b
II.e
III.m
IV.a
IV.d
IV.t
IV.x
IV.af
IV.ag
V.g
VI.a
VI.i
VI.t
VII.a
VII.b
VIII.a
IX.a
IX.d
IX.r
IX.ab
IX.ac
X.a
X.c
X.d
X.e
X.f
X.i
X.j
X.l
X.m
X.o
X.p
X.u
X.w
X.ao
X.ap
X.ax
X.az
X.bj
XI.l
XI.v
XI.ad
XI.ar
XI.as
XI.av
XII.a
XII.c
XII.d
XII.f
XII.h
XII.n
XII.o
XII.s
XII.t
XII.ak
XII.az
XII.bd
XVI.k
XVI.v
XVI.w
XVI.bj
XVI.bk
XVI.bv
XVIII.a
XVIII.b
XVIII.c
XIX.a
XIX.b
XIX.d
XIX.e
XIX.f
XIX.j
XIX.o
XIX.x
XIX.ae
XIX.al
XIX.bx
XIX.co
XIX.cr
XIX.cv
XX.b
XX.c
XX.e
XX.g
XX.q
XX.r
Lorlatinib
I.a
I.b
I.ae
II.e
VII.b
IX.r
Nivolumab
I.a
I.b
I.c
I.d
I.e
I.f
I.i
I.ae
I.ak
II.b
II.e
III.g
III.j
III.m
IV.a
IV.d
IV.t
IV.w
IV.x
IV.af
IV.ag
V.g
V.au
VI.a
VI.m
VII.b
IX.a
IX.d
IX.h
IX.r
IX.y
IX.ab
X.a
X.d
X.f
X.i
X.l
X.m
X.o
X.p
X.u
X.w
X.ae
X.az
XI.as
XI.bi
XII.c
XII.d
XII.h
XII.o
XII.t
XII.ak
XII.az
XIII.c
XIII.d
XVI.i
XVI.v
XVI.w
XVI.ac
XVI.ad
XVI.ak
XVIII.a
XVIII.b
XVIII.c
XIX.d
XIX.e
XIX.r
XIX.al
XIX.am
XIX.au
XX.a
XX.c
XX.g
XX.ai
Osimertinib
I.a
I.b
I.c
I.i
I.ae
I.aw
I.ba
III.a
XII.n
XII.q
XII.s
XII.ak
XVIII.a
XVIII.c
XIX.a
XIX.b
XXIII.a
XXIII.e
Loading more…